You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
With the OptiVol™ 2.0 Fluid Status Monitoring feature (available on select CRT-D and CRT-P devices), you can track intrathoracic impedance changes over time to help you assess congestion in heart failure patients.1,2
Many trials have looked at the clinical utility of OptiVol 2.0 as a tool in managing heart failure patients.
Topic | Clinical Evidence | Main Supporting Trials* |
---|---|---|
Impedance monitoring |
Intrathoracic impedance:
|
MID-HeFT Trial1 |
Heart failure hospitalization |
OptiVol fluid index threshold crossings:
Combined/integrated diagnostics:
|
PARTNERS HF17 OFISSER18 |
Weight monitoring, 6-MHW, BNP marker |
|
AST19 |
Heart failure readmissions |
|
PARTNERS HF17, OFFISER18 FAST19, CONNECT21 |
Arrhythmias |
|
See references for supporting studies and case studies |
Mortality risk |
|
Study by the Heart and Vascular Institute at the Cleveland Clinic27 |
Additional trials support these statements, see references for additional information.
Yu CM, et al. Circulation. 2005;112:841-848.
Abraham WT, et al. J Card Fail. 2009;15:813.
Germany R, et al. Am J Cardiol. 2007;99:11G-16G.
Small RS, et al. Am J Cardiol. 2007;99:17G-22G.
Vollmann D, et al. Eur Heart J. 2007;28:1835-1840.
Repoley J, et al. J Card Fail. 2006;12(suppl): S66.
Patient Case: LV Lead Dislodgement and Pocket Revision. Courtesy of R. Ward Pulliam and Jill Repoley, NP. The Heart Group and Lancaster General Hospital, Lancaster, PA. 2006 Medtronic Inc., data on file, UC200602091 EN
Small R, et al. J Card Fail. 2007;13(suppl):S113-S114.
Tang W, et al. J Card Fail. 2007;13(suppl):S182.
Braunschweig F, et al. Am J Cardiol. 2005;95:1104-1107.
Rathman L. Am J Cardiol. 2007;99:29G-33G.
Wang L. Am J Cardiol. 2007;99:3G-10G.
Abraham W, et al. Heart Rhythm. 2005;2(suppl):S65-S66.
Wang L, et al. Pacing Clin Electrophysiol. 2005;28:404-411.
Lüthje L, et al. Eur J Heart Fail. 2007;9:716-722.
Medtronic Viva XT CRT-D System Reference Guides.
Whellan DJ, et al. J Am Coll Cardiol. 2010;55:1803-1810.
Small RS, et al. J Card Fail. 2009;15:475-481.
Abraham WT, et al. Congest Heart Fail. 2011;17:51-55.
Gulati SK, et al. J Card Fail. 2010;16(suppl):S65.
Crossley GH, et al. J Am Coll Cardiol. 2011;57:1181-1190.
Whellan DJ, et al. Am J Cardiol. 2013;111:79-84.
Small RS, et al. J Card Fail. 2012;18(8 Suppl):S50. (abstract HFSA).
Moore HJ, et al. Pacing Clin Electrophysiol. 2010 33:960-966.
Andriulli J, et al. Int J Cardiol. 2008;123:333-334.
Jhanjee R, et al. Circ Arrhythm Electrophysiol. 2009;2:488-494.
Tang WH, et al. Eur Heart J. 2012;33:2189-2196.
Sources: Medtronic Protecta™ XT DR Clinician Manual; Medtronic Protecta™ XT CRT-D Clinician Manual